subject: Muscular Dystrophy - Pipeline Assessment And Market Forecasts To 2017 Aarkstore Enterprise [print this page] Aarkstore announce a new report "Muscular Dystrophy - Pipeline Assessment and Market Forecasts to 2017" through its vast collection of market research report.
Muscular Dystrophy - Pipeline Assessment and Market Forecasts to 2017 report is an essential source of information and analysis on the global muscular dystrophy therapeutics market and pipeline The report identifies the key trends shaping and driving the global muscular dystrophy therapeutics market.
The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global muscular dystrophy therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
We have estimated the global muscular dystrophy therapeutics market to be valued at $115 m in 2009. It is expected to increase to $156 m with a Compound Annual Growth Rate (CAGR) of (3.9%) by 2017. There is a high unmet need in the current Meningitis Preventive Vaccines market in terms of both safety and efficacy profile. New high potential drugs muscular dystrophy therapeutics are expected to come in the market after 2017.
Scope
The report provides information on the key drivers and challenges of the muscular dystrophy therapeutics market. Its scope includes:
- Annualized global muscular dystrophy therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major classes such as exon inhibitor and antioxidants.
- Analysis of the current and future competition in the global muscular dystrophy therapeutics market. Key market players covered are PTC therapeutics, Genzyme corporation, Santhera pharmaceuticals, Takeda Biopharmaceuticals, Avi Biopharma, Insmed Incorporated, GlaxoSmithKline, Prosena Therapeutics B.V.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the muscular dystrophy therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Meningitis Preventive Vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Meningitis Preventive Vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Meningitis Preventive Vaccines market landscape? Identify, understand and capitalize.
